Details of the Drug

General Information of Drug (ID: DM0FXMZ)

Drug Name
APG-101
Synonyms
CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Phase 2 [1]
Cross-matching ID
TTD ID
D0N4JI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis mediating surface antigen FAS (FAS) TTF0RCZ TNR6_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cerebrovascular ischaemia
ICD Disease Classification 8B1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apoptosis mediating surface antigen FAS (FAS) DTT FAS 1.08E-03 -0.69 -2.65
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01071837) APG101 in Glioblastoma. U.S. National Institutes of Health.
2 Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.